Skip to main content
. 2016 Apr 15;143(8):1271–1283. doi: 10.1242/dev.131961

Fig. 7.

Fig. 7.

CARM1-mediated methylation of BAF155 influences assembly of the BAF complex and lineage specification. (A) Methylated BAF155 in E3.5 and E4.5 embryos. Methylated BAF155 was detectable at only low levels in Carm1−/− embryos. (B) The distribution of H3R17me2 at E4.5. (C) Methylation of BAF155 is reduced in embryos treated with a CARM1-specific inhibitor (CARMi) and is unaffected by DMSO carrier. (D) NANOG+ cells in CARMi-treated embryos show reduced FRAP recovery of BAF155-mCherry compared with NANOG+ in DMSO-treated embryos. (E) NANOG+ cells (CARMi) have a higher immobile fraction of BAF155 protein (75±3.6%) than NANOG+ cells in DMSO (86.87±2%). (F) The frequency of interactions between BAF155 and BRG1 is comparably increased in EPI cells (dashed outline) of Carm1 null and CARMi E4.5 embryos (arrows), in contrast to EPI cells of wild-type and DMSO-treated embryos. (G) The fluorescence intensity generated by BAF155-BRG1 association is increased in EPI cells of Carm1−/− compared with wild-type embryos, and in CARMi-treated compared with DMSO-treated embryos. (H) The number of NANOG+ cells is decreased in Carm1 null and CARMi embryos. Error bars represent s.e.m. *P<0.05, **P<0.001, Student's t-test. Scale bars: 10 μm.